Ivermectin significantly reduces COVID-19 mortality risk

According to the latest research, published in American Journal of Therapeutics, ivermectin may reduce mortality risk in mild-to-moderate COVID-19 patients by an average of 62%, writes MedicalBrief (30 June 2021).
“The findings will reignite the ongoing debate between those who believe that the repurposed anti-parasitic should be given emergency regulatory clearance worldwide and those who have rejected the evidence as too scanty.
“The study further suggests that risk of death among hospitalised patients treated with Ivermectin was 2.3%, compared to 7.8% for those who were not. The team said that there may be no benefit for COVID-19 patients in need of mechanical ventilation”.

Other news